ESSA Pharma

ESSA Pharma EBIT per Share

Delisted

The EBIT per Share of ESSA Pharma (EPIX) as of Oct 24, 2026 is -0.78 USD. In the previous year, EBIT per Share was -0.73 USD — a change of 6.64% (lower).

EBIT per Share

-0.78USD

YoY

6.64%

Last updated:

EBIT per Share of ESSA Pharma is 2024 -0.78 USD. EBIT per Share of ESSA Pharma was 2023 -0.73 USD. It decreases by 6.64% lower compared to the previous year.

The ESSA Pharma EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-0.73 USD
Jan 1, 2024
-0.78 USD
Jan 1, 2025 (e)
-0.76 USD
Jan 1, 2026 (e)
-0.51 USD
Jan 1, 2027 (e)
-0.51 USD
Jan 1, 2028 (e)
-0.52 USD
Jan 1, 2029 (e)
9.75 USD
Jan 1, 2030 (e)
0.00 USD
The ESSA Pharma EBIT per Share history
YEAREBIT per ShareYoY
est0.00USD-100.00%
est9.75USD-1,959.30%
est-0.52USD+3.47%
est-0.51USD0.00%
est-0.51USD-33.13%
est-0.76USD-2.51%
-0.78USD+6.64%
-0.73USD-13.16%
-0.84USD-13.07%
-0.97USD-9.44%
-1.07USD-26.01%
-1.44USD-40.28%
-2.41USD-78.21%
-11.08USD-20.04%
-13.85USD-19.55%
-17.22USD+356.79%
-3.77USD+188.24%
-1.31USD-50.28%
-2.63USD+71.76%
-1.53USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ESSA Pharma Stock analysis

What does ESSA Pharma do? ESSA Pharma Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of prostate cancer and other types of cancer. The company is headquartered in Vancouver, Canada and was founded in 2009. The history of ESSA Pharma Inc begins with the discovery of a new approach to treating prostate cancer by the company's founders. They discovered that a combination of an androgen receptor inhibitor and a NEDDylation signaling inhibitor could offer a new and effective approach to treating prostate cancer. Based on this discovery, they founded ESSA Pharma Inc to further develop this therapy. ESSA Pharma Inc's business model is based on the discovery, development, and commercialization of therapies for the treatment of prostate cancer and other types of cancer. The company has a pipeline of products in various clinical phases aimed at effectively combating prostate cancer and other types of cancer. ESSA Pharma Inc operates in two main divisions: research and development, and marketing and sales. The company's research and development department is dedicated to identifying and developing new compounds tailored to the specific needs of patients with prostate cancer. The company also works closely with researchers and physicians to test the efficacy of its products in treatment protocols and clinical practice. The second division of ESSA Pharma Inc deals with the marketing and sales of its products. Here, the company works closely with pharmaceutical manufacturers and other companies to market and sell its products worldwide. The company also has its own sales department that serves customers worldwide. ESSA Pharma Inc currently offers several products in different stages of clinical trials. These include EPI-506, an androgen receptor inhibitor currently being used in a Phase 1 study for the treatment of prostate cancer, and EPI-7386, a NEDDylation signaling inhibitor currently in a Phase 1 study for the treatment of prostate cancer. In addition, ESSA Pharma Inc has formed partnerships with other companies to further develop its technology platform and pipeline of cancer therapies. For example, the company is collaborating with Bayer Healthcare to advance the development of EPI-7386. Overall, ESSA Pharma Inc is an innovative and emerging biotech company focused on the development of therapies for the treatment of prostate cancer and other types of cancer. The company is pursuing an ambitious strategy and has already achieved promising results in the development of new compounds for the treatment of prostate cancer. ESSA Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ESSA Pharma stock

EBIT per Share of ESSA Pharma is -0.78 USD in 2024.

EBIT per Share of ESSA Pharma changed from -0.73 USD to -0.78 USD, representing a 6.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share ESSA Pharma since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ESSA Pharma

All Key Metrics — ESSA Pharma